文献速递浆细胞疾病

泊马度胺、地塞米松联合聚乙二醇脂质体多柔比星治疗复发或难治性多发性骨髓瘤患者的安全性与疗效

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
PubMed 文献 · Br J Haematol · 2017-11-21

本研究评估泊马度胺(POM)联合地塞米松(DEX)40 mg及聚乙二醇脂质体多柔比星(PLD)5 mg/m²(后两者于28天周期第1、4、8、11天给药)治疗复发/难治性多发性骨髓瘤(MM)的剂量与疗效。1期确定POM最大耐受剂量为4 mg并用于2期(要求来那度胺难治),但≥3级中性粒细胞减少见于10/17(59%)患者,剂量降至3 mg。2期POM 3 mg组总缓解率39%、4 mg组31%,临床获益率分别为51%和44%,中位无进展生存期5.4个月。

要点

  • 1期确定POM最大耐受剂量为4 mg,2期用于来那度胺难治患者。
  • ≥3级中性粒细胞减少见于10/17(59%)患者,POM剂量降至3 mg。
  • 2期POM 3 mg组总缓解率39%,4 mg组31%。

核心结论

  • POM联合PLD和DEX是复发/难治性MM患者(包括来那度胺难治者)的一种治疗选择。

研究设计与样本

  • 研究纳入复发/难治性MM患者,评估POM联合DEX 40 mg及PLD 5 mg/m²(后两者于28天周期第1、4、8、11天给药)的1期和2期试验;2期要求患者对来那度胺难治。

主要发现

  • 1期确定POM最大耐受剂量为4 mg,并用于2期。
  • ≥3级中性粒细胞减少见于10/17(59%)患者,随后POM剂量降至3 mg。
  • 中位无进展生存期为5.4个月(范围0.3-29.0+个月)。
  • 2期POM 3 mg组总缓解率为39%,POM 4 mg组为31%。
  • 2期POM 3 mg组临床获益率为51%,POM 4 mg组为44%。

临床怎么用

  • 作者认为,POM联合PLD和DEX是复发/难治性MM患者(包括来那度胺难治者)的一种治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory drugs including thalidomide, lenalidomide (LEN) and pomalidomide (POM), are effective for treating multiple myeloma (MM). POM has shown enhanced efficacy with dexamethasone (DEX). Pegylated liposomal doxorubicin (PLD) with bortezomib is US Food and Drug Administration-approved for treating MM. PLD with LEN or thalidomide has shown efficacy for MM patients. LEN with DEX, PLD and bortezomib achieves high response rates. We evaluated the combination of POM with DEX 40 mg and PLD 5 mg/m2 with the latter two drugs administered on days 1, 4, 8 and 11 on a 28-day cycle for the treatment of relapsed/refractory MM patients. During Phase 1, the maximum tolerated dose of POM was 4 mg, and was used in Phase 2, which also required patients to be refractory to LEN. However, neutropenia ≥ grade 3 was observed in 10/17 (59%) patients, and the dose was lowered to 3 mg. Median PFS was 5·4 months (range, 0·3-29·0 + months). Overall response rates for patients in Phase 2 were 39% and 31% among subjects receiving POM at 3 mg and 4 mg, respectively, and clinical benefit rates were 51% and 44%, respectively. POM, PLD and DEX is a treatment option for relapsed/refractory MM patients including those who are refractory to LEN.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cohen A, Spektor TM, Stampleman L, et al. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. Br J Haematol. 2017. PMID: 29164606. doi:10.1111/bjh.14992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。